Enlivex Therapeutics Ltd Stock Price, News & Analysis

Enlivex Therapeutics announced the Israeli Ministry of Health's authorization to begin a Phase I/II clinical trial for Allocetra™ combined with chemotherapy in patients with peritoneal metastases from solid tumors. This trial responds to the urgent need for new treatments for this terminal condition, where current therapies offer limited survival benefits. Enlivex aims to enroll approximately 12 patients, with the primary endpoint focused on safety and adverse events. The study is set to initiate in Q3 2022, following promising preclinical data suggesting Allocetra™ could enhance cancer treatment efficacy.

Enlivex Therapeutics Ltd. has announced promising preclinical findings regarding the use of Allocetra™ in combination with anti-PD1 checkpoint inhibitors for treating ovarian cancer. Conducted in collaboration with Yale Cancer Center, the study showed a survival probability of up to 50% and an 83% increase in survival duration compared to untreated groups. This highlights Allocetra’s potential to enhance checkpoint inhibitor efficacy in difficult-to-treat cancers. The results will be presented at the ASCO Annual Meeting from June 3-7, 2022.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been awarded a grant of approximately $1.2 million from the Israel Innovation Authority for its ongoing sepsis clinical trial in 2022. This brings the total non-dilutive funding from the IIA to about $7.8 million since the inception of their partnership. Enlivex is currently recruiting patients for its Phase IIb trial of Allocetra^TM, aimed at treating organ dysfunction associated with sepsis. Allocetra^TM is designed to reprogram macrophages, potentially addressing unmet medical needs in critical conditions.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) appointed Roger J. Pomerantz, M.D., as Vice Chairman of its Board of Directors. Dr. Pomerantz is a seasoned pharmaceutical expert with a history of leading significant business developments, including over 150 transactions at Merck & Co. and roles at Johnson & Johnson and Seres Therapeutics. He expressed excitement about Enlivex's Allocetra cell therapy, which aims to restore macrophage function in diseases like sepsis and solid tumors. The company anticipates a cash runway into Q3 2024, positioning it well for future growth.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the H.C. Wainwright Global Investment Conference from May 23–26, 2022. The company's presentation will be pre-recorded and accessible throughout the event. Enlivex is developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to combat diseases such as sepsis and solid tumors. Allocetra™ targets non-homeostatic macrophages that worsen these conditions, potentially offering a new immunotherapeutic approach for serious medical needs.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in the Allogeneic Cell Therapies Summit 2022 and the 20th Biomed Israel Conference. Presentations include topics on their innovative therapy, Allocetra™, targeting solid tumors and cytokine storms linked to sepsis and COVID-19. Key details include a presentation on 'Next Generation Allogeneic Modality for Solid Tumors' on May 10, 2022, and two presentations at the Biomed Israel Conference on May 10 and 12. The focus is on the therapeutic potential of Allocetra™ in treating severe conditions.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced promising preclinical results for its cell therapy Allocetra™ combined with immune checkpoint inhibitors in treating mesothelioma. A study revealed up to 100% survival in mice receiving the combination treatment versus 0% survival in untreated mice. Allocetra™ alone achieved a 28.5% survival rate. This positions Allocetra™ as a potential innovative therapy for difficult-to-treat solid tumors, prompting plans for clinical trials in 2022 to evaluate its efficacy in patients with advanced-stage cancers.

Enlivex Therapeutics Ltd. announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163, securing intellectual property protection for treating sepsis with Allocetra™ until at least 2036. CEO Oren Hershkovitz emphasized that these patents strengthen their sepsis program, particularly for pneumonia, urinary, and biliary infections. The company is advancing its Phase II trial of Allocetra™, designed to reprogram macrophages and address life-threatening conditions. Enlivex aims to expand its patent portfolio globally.

Enlivex Therapeutics (Nasdaq: ENLV) announced the acceptance of an abstract for a poster presentation at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022, at the McCormick Place in Chicago.

The poster, titled "In-vivo reprogramming macrophages and dendritic cells with Allocetra-OTS", covers successful antitumor therapy. The presentation will take place on June 5, 2022, between 8:00 AM and 11:00 AM CDT.

Allocetra™ aims to restore macrophage homeostasis, presenting a potential new immunotherapeutic approach for treating various diseases.